IDiyas

For the Inventor, By the Inventor

Milton, MA, United States of America

Andrew M Wollacott

USPTO Granted Patents = 18 

 

Average Co-Inventor Count = 6.6

ph-index = 3

Forward Citations = 24(Granted Patents)


Location History:

  • Milton, MA (US) (2019 - 2024)
  • Waltham, MA (US) (2023 - 2024)

Company Filing History:

goldMedal18 out of 37 
 
Visterra, Inc.
 patents

Years Active: 2019-2025

Loading Chart...
Loading Chart...
18 patents (USPTO):Explore Patents
1. 12415865 - Antibody molecules to C5AR1 and uses thereof (2025-09-16),
2. 12338291 - Humanized antibody molecules to CD138 and uses thereof (2025-06-24),
3. 12264203 - Humanized complement 5a receptor 1 antibodies and methods of use thereof (2025-04-01),
4. 12227587 - Humanized complement 5A receptor 1 antibodies and methods of use thereof (2025-02-18),
5. 12187807 - Antibody molecules to C5AR1 and uses thereof (2025-01-07),
6. 12091451 - Method of using antibody molecules to detect a proliferation-inducing ligand (APRIL) (2024-09-17),
7. 11969476 - Antibody molecule-drug conjugates and uses thereof (2024-04-30),
8. 11912781 - Humanized complement 5A receptor 1 antibodies and methods of use thereof (2024-02-27),
9. 11890319 - Antibody molecule-drug conjugates and uses thereof (2024-02-06),
10. 11858980 - Engineered polypeptides and uses thereof (2024-01-02),
11. 11773179 - Antibody molecules to C5aR1 and uses thereof (2023-10-03),
12. 11168131 - Antibody molecule-drug conjugates and uses thereof (2021-11-09),
13. 11136385 - Methods of treating IgA nephropathy by administering an anti-APRIL (a proliferation-inducing ligand) antibody molecule (2021-10-05),
14. 10981982 - Nucleic acid molecules encoding antibodies to a proliferation-inducing ligand (APRIL) (2021-04-20),
15. 10968270 - Antibody molecules to a proliferation-inducing ligand (APRIL) (2021-04-06),

Title: The Innovative Contributions of Andrew M Wollacott

Introduction

Andrew M Wollacott is a prominent inventor based in Milton, MA, known for his significant contributions to the field of biotechnology. With a total of 18 patents to his name, Wollacott has made remarkable advancements in the development of antibody molecules that have the potential to treat various medical disorders.

Latest Patents

Among his latest patents is the invention of antibody molecules to C5aR1, which specifically bind to the C5a receptor. These antibody molecules are disclosed for their potential use in treating, preventing, and diagnosing disorders such as ANCA-vasculitis. Another notable patent involves humanized antibody molecules to CD138, which are designed to specifically bind to CD138. These humanized antibody molecules can be utilized in the treatment, prevention, and diagnosis of disorders like multiple myeloma.

Career Highlights

Wollacott's career is marked by his role at Visterra, Inc., where he has been instrumental in advancing innovative therapeutic solutions. His work has not only contributed to the scientific community but has also paved the way for new treatment options for patients suffering from serious health conditions.

Collaborations

Wollacott has collaborated with notable colleagues, including Karthik Viswanathan and Boopathy Ramakrishnan, to further enhance the research and development of antibody therapies.

Conclusion

Andrew M Wollacott's innovative work in the field of biotechnology exemplifies the impact of dedicated inventors on medical science. His patents and collaborations continue to inspire advancements in treatment options for various disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…